Novo Nordisk's $16.5 Billion Acquisition Reshapes Pharmaceutical Landscape

As Novo Nordisk addresses its supply issues, the pharmaceutical industry may face new challenges, particularly for companies considering outsourcing production to major competitors. Novo Nordisk has received regulatory approval to acquire three major production sites that will be used to manufacture its bestselling drug Wegovy and other similar products, which is expected to alleviate the supply shortages of these medications. However, this series of acquisitions is part of a larger industry restructuring that could have far-reaching effects on the pharmaceutical sector.

In recent years, pharmaceutical companies have increasingly relied on external contractors for drug testing and production. Novo Nordisk's parent company, Novo Holdings, announced the acquisition of major contract manufacturer Catalent for $16.5 billion, after which Novo Nordisk will purchase three Catalent production sites for $11 billion. Upon completion of the acquisition, Novo Nordisk will own three highly specialized plants that were previously part of Catalent, dedicated to the final-stage production of Wegovy and similar medications. Novo Nordisk stated that it will fulfill all customer obligations at these facilities.

The remaining shares of Catalent will be held by Novo Holdings, which controls three-quarters of the voting rights and over one-quarter of the equity in Novo Nordisk. Despite the presence of other large contract manufacturers, such as Lonza Group and Thermo Fisher Scientific, Catalent is a major player in this field, claiming that one out of every 28 doses of pharmaceuticals and consumer health products globally is produced by them. Moreover, over half of the new drugs approved by the U.S. Food and Drug Administration in the past decade have been developed by Catalent.

Competitors, regulators, and some political figures have called for a halt to this transaction, creating uncertainty regarding its completion. Novo Nordisk's American Depositary Receipts rose 1.1% to $108.08 following the regulatory approval. Market reactions to the completion of the Catalent deal may be influenced by the anticipated results of clinical trials for the new generation weight loss drug CagriSema, which are expected to be announced soon.

The competitors directly impacted by this deal include Eli Lilly, which is also working to meet demand for its products Zepbound and Mounjaro, which compete with Novo Nordisk's Wegovy and Ozempic. Eli Lilly will now face the challenge of Novo Nordisk's upgraded production capabilities. Eli Lilly's stock fell 1.3% to $779.02. During the earnings call in August, Eli Lilly CEO David Ricks stated that the company has the capability to produce Zepbound but also expressed concerns about a major competitor simultaneously becoming a contract manufacturer.

A spokesperson for Eli Lilly stated that the company has utilized Catalent to produce a "wide range" of drugs and expects Catalent to meet its obligations. Eli Lilly is actively building its own manufacturing facilities to achieve long-term strategic goals. Catalent CEO Alessandro Maselli stated in an open letter to clients that the company will continue to operate as a private entity under Novo Holdings and is committed to providing unparalleled service and creating new job opportunities.

Other pharmaceutical companies have remained silent on this series of transactions. A spokesperson for Roche Holdings declined to comment on the statement made over the weekend and expressed no concern about the deal's impact on Roche. CEO Thomas Schinecker noted in October that the reduction of independent contract manufacturers could lead to decreased competition, which may pose challenges for smaller companies.